Literature DB >> 3898085

Identification of an inducible form of cytochrome P-450 in human liver.

P B Watkins, S A Wrighton, P Maurel, E G Schuetz, G Mendez-Picon, G A Parker, P S Guzelian.   

Abstract

It has not yet been determined whether human liver contains inducible cytochromes P-450 similar to those that catalyze the oxidative metabolism of foreign substances in animals. We carried out immunoblot analyses of liver microsomes isolated from eight patients and found that each contained a cytochrome P-450, termed HLp, that reacted with antibodies directed against P-450p, a rat liver cytochrome that is inducible by the anti-glucocorticoid pregnenolone-16 alpha-carbonitrile, by glucocorticoids, by anti-seizure drugs, and by such macrolide antibiotics as triacetyloleandomycin. In the two patients who received dexamethasone and anti-seizure medications and in the one patient who was given triacetyloleandomycin, the concentrations of immunoreactive HLp and the ability to demethylate erythromycin and/or to convert triacetyloleandomycin to a metabolite that forms a spectral complex with cytochrome P-450 heme (catalytic properties unique to P-450p in rat liver) were significantly higher as compared to the values for patients who received no inducing drugs. We purified HLp to homogeneity and found that it was immunochemically related to P-450p and to its homologue in the rabbit (LM3c), actively demethylated erythromycin in a reconstituted system, exhibited electrophoretic mobility identical to that of P-450p, and shared 57% homology in its NH2-terminal amino acid sequence with that of a pregnenolone-16 alpha-carbonitrile-inducible rat cytochrome P-450. We conclude that HLp is a human representative of the multigene family of the glucocorticoid-inducible cytochromes P-450.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898085      PMCID: PMC391043          DOI: 10.1073/pnas.82.18.6310

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

2.  Effects of o,p'-DDD on cortisol and 6-beta-hydroxycortisol secretion and metabolism in man.

Authors:  D K Fukushima; H L Bradlow; L Hellman
Journal:  J Clin Endocrinol Metab       Date:  1971-02       Impact factor: 5.958

3.  Effect of intensive occupational exposure to DDT on phenylbutazone and cortisol metabolism in human subjects.

Authors:  A Poland; D Smith; R Kuntzman; M Jacobson; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

4.  Phenobarbital-induced drug metabolism in man.

Authors:  G Kellermann; M Luyten-Kellermann
Journal:  Toxicol Appl Pharmacol       Date:  1977-01       Impact factor: 4.219

5.  Separation, purification, and characterization of a novel form of hepatic cytochrome P-450 from rats treated with pregnenolone-16 alpha-carbonitrile.

Authors:  N A Elshourbagy; P S Guzelian
Journal:  J Biol Chem       Date:  1980-02-25       Impact factor: 5.157

6.  Induction of the unspecific microsomal hydroxylase in the human liver.

Authors:  H Remmer; B Schoene; R A Fleischmann
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

7.  Determination of drug metabolizing enzymes in needle biopsies of human liver.

Authors:  B Schoene; R A Fleischmann; H Remmer; H F von Oldershausen
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

8.  Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes.

Authors:  T A van der Hoeven; M J Coon
Journal:  J Biol Chem       Date:  1974-10-10       Impact factor: 5.157

9.  The [14C]-aminopyrine breath test. A comparison of different forms of analysis.

Authors:  D A Henry; G Sharpe; S Chaplain; S Cartwright; G Kitchingman; G D Bell; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

10.  Alterations in drug metabolism in workers exposed to polychlorinated biphenyls.

Authors:  A P Alvares; A Fischbein; K E Anderson; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

View more
  51 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

3.  Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.

Authors:  A G Pinto; J Horlander; N Chalasani; M Hamman; A Asghar; D Kolwankar; S D Hall
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

4.  A malleable catalyst dominates the metabolism of drugs.

Authors:  F Peter Guengerich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-05       Impact factor: 11.205

Review 5.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

6.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

Authors:  P B Watkins; S A Murray; L G Winkelman; D M Heuman; S A Wrighton; P S Guzelian
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

7.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Authors:  K Yoshimoto; H Echizen; K Chiba; M Tani; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

8.  In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.

Authors:  M Sarkar; R E Polk; P S Guzelian; C Hunt; H T Karnes
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

9.  Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase.

Authors:  P Fritz; E Behrle; P Beaune; M Eichelbaum; H K Kroemer
Journal:  Histochemistry       Date:  1993-06

10.  Identification of P450 enzymes involved in metabolism of verapamil in humans.

Authors:  H K Kroemer; J C Gautier; P Beaune; C Henderson; C R Wolf; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.